Should We Perform Repeated Re-Biopsy for the Detection of T790M Mutation?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Epidermal growth factor receptor (EGFR) T790M mutations have been detected in the second or third rebiopsy, even if the T790M mutation was not identified in the first rebiopsy. This meta-analysis investigated the EGFR T790M mutation detection rates and its additional advantages with repeated rebiopsies. Materials and Methods We searched through the PubMed and EMBASE databases up to June 2022. Studies reporting rebiopsy to identify the EGFR T790M mutation in case of disease progression among patients with advanced non-small cell lung cancer and multiple rebiopsies were included. The quality of the included studies was checked using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Results Eight studies meeting the eligibility criteria, reporting 1,031 EGFR mutation–positive patients were selected. The pooled EGFR T790M mutation detection rate of the first and repeated rebiopsies were 0.442 (95% confidence interval [CI], 0.411 to 0.473; I2=84%; p < 0.01) and 0.465 (95% CI, 0.400 to 0.530; I2=69%; p < 0.01), respectively. Overall, the pooled detection rate of EGFR T790M mutation was 0.545 (95% CI, 0.513 to 0.576), which increased by 10.3% with repeated rebiopsies. Conclusion This meta-analysis identified that repeated rebiopsy increases the detection rate of EGFR T790M mutation by 10.3%, even if EGFR T790M mutation is not detected in the first rebiopsy. Our results indicate that the spatiotemporal T790M heterogeneity can be overcome with repeated rebiopsy.
Abstract
Purpose Epidermal growth factor receptor (EGFR) T790M mutations have been detected in the second or third rebiopsy, even if the T790M mutation was not identified in the first rebiopsy. This meta-analysis investigated the EGFR T790M mutation detection rates and its additional advantages with repeated rebiopsies. Materials and Methods We searched through the PubMed and EMBASE databases up to June 2022. Studies reporting rebiopsy to identify the EGFR T790M mutation in case of disease progression among patients with advanced non-small cell lung cancer and multiple rebiopsies were included. The quality of the included studies was checked using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Results Eight studies meeting the eligibility criteria, reporting 1,031 EGFR mutation–positive patients were selected. The pooled EGFR T790M mutation detection rate of the first and repeated rebiopsies were 0.442 (95% confidence interval [CI], 0.411 to 0.473; I2=84%; p < 0.01) and 0.465 (95% CI, 0.400 to 0.530; I2=69%; p < 0.01), respectively. Overall, the pooled detection rate of EGFR T790M mutation was 0.545 (95% CI, 0.513 to 0.576), which increased by 10.3% with repeated rebiopsies. Conclusion This meta-analysis identified that repeated rebiopsy increases the detection rate of EGFR T790M mutation by 10.3%, even if EGFR T790M mutation is not detected in the first rebiopsy. Our results indicate that the spatiotemporal T790M heterogeneity can be overcome with repeated rebiopsy.
참고문헌 (29)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75ra26~ (2011)
- Camidge DR, "Acquired resistance to TKIs in solid tumours : learning from lung cancer", Nat Rev Clin Oncol, 11, pp.473~481 (2014)
- Ahn MJ, "Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer : results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study", Lancet Oncol, 20, pp.1681~1690 (2019)
- Chabon JJ, "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients", Nat Commun, 7, pp.11815~ (2016)
- "NSCLC (version 2. 2023)" (2023)[URL]
- Seto T, "Real-world EGFR T790M testing in advanced non-small-cell lung cancer : a prospective observational study in Japan", Oncol Ther, 6, pp.203~215 (2018)
- Kim I, "Favorable conditions for the detection of EGFR T790M mutation using plasma sample in patients with non-small-cell lung cancer", Cancers(Basel), 15, pp.1445~ (2023)
- Ichihara E, "Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer", Oncotarget, 9, pp.29525~29531 (2018)
- Ninomaru T, "Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first", second generation EGFR-TKIs, 2021, pp.12, 746~751
- Kudo K, "First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer : CS-Lung-003 prospective observational registry study", J Cancer Res Clin Oncol, 148, pp.1869~1877 (2022)
- McInnes MD, "Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies : The PRISMA-DTA Statement", JAMA, 319, pp.388~396 (2018)
- Kuiper JL, "Incidence of T790M mutation in(sequ-ential)rebiopsies in EGFR-mutated NSCLC-patients", Lung Cancer, 85, pp.19~24 (2014)
- Lee K, "Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer", Lung Cancer, 130, pp.87~92 (2019)
- Chiang CL, "Post-progression survival in secondary EGFR T790M-mutated non-small-cell lung cancer patients with and without osimertinib after failure of a previous EGFR TKI", Target Oncol, 15, pp.503~512 (2020)
- Chu Q, "Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer : a Canadian experience", Curr Oncol, 27, pp.27~33 (2020)
- Whiting PF, "QUADAS-2 : a revised tool for the quality assessment of diagnostic accuracy studies", Ann Intern Med, 155, pp.529~536 (2011)
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
- Hunter JP, "In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias", J Clin Epidemiol, 67, pp.897~903 (2014)
- Hata A, "Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI", J Thorac Oncol, 10, pp.1553~1559 (2015)
- Gregorc V, "Intratumoral cellular heterogeneity : implications for drug resistance in patients with non-small cell lung cancer", Cancers(Basel), 13, pp.2023~ (2021)
- Kim H, "Repeat biopsy of patients with acquired resistance to EGFR TKIs : implications of biopsy-related factors on T790M mutation detection", Eur Radiol, 28, pp.861~868 (2018)
- Hong KS, "Endobronchial ultrasound-guided re-biopsy of non-small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment", Thorac Cancer, 14, pp.363~370 (2023)
- Oxnard GR, "Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer : distinct natural history of patients with tumors harboring the T790M mutation", Clin Cancer Res, 17, pp.1616~1622 (2011)
- Lin MW, "Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor treatment", Ann Thorac Surg, 116, pp.111~119 (2023)
- Uozu S, "Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies", BMC Pulm Med, 17, pp.175~ (2017)
- Chan DL, "Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients", Exp Mol Pathol, 116, pp.104515~ (2020)
- Li X, "Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer", Oncotarget, 8, pp.100801~100818 (2017)